Bromisovalum

CHEMBL1515611 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
223.1 g/mol
LogP
1.1
Phase
4

A brominated sedative and hypnotic agent that was used historically to treat anxiety and insomnia. It belongs to the bromide-containing compounds that were widely used before benzodiazepines became available. It is no longer in clinical use due to the risk of bromism with prolonged administration and the availability of safer alternatives.

Khối lượng phân tử

223,0700 g/mol

LogP

1,10

TPSA

72,20 Ų

Lipinski RO5

Đạt

Cơ chế tác dụng

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)C(Br)C(=O)NC(N)=O

InChI

InChI=1S/C6H11BrN2O2/c1-3(2)4(7)5(10)9-6(8)11/h3-4H,1-2H3,(H3,8,9,10,11)

Molecular Formula

C6H11BrN2O2

HBD / HBA

2 / 2

Liên kết có thể quay

2

Nguyên tử nặng

11

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A brominated sedative and hypnotic agent that was used historically to treat anxiety and insomnia. It belongs to the bromide-containing compounds that were widely used before benzodiazepines became available. It is no longer in clinical use due to the risk of bromism with prolonged administration and the availability of safer alternatives.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Bromisovalum is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1515611. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2447. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.